1. Strosberg J.R., Coppola D., Klimstra D.S., Phan A.T., Kulke M.H., Wiseman G.A., Kvols L.K.; North American Neuroendocrine Tumor Society (NANETS). The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010 Aug; 39(6): 799-800. https://doi.org/10.1097/MPA.0b013e3181ebb56f.
2. Yao J.C., Hassan M., Phan A., Dagohoy C., Leary C., Mares J.E., Abdalla E.K., Fleming J.B., Vauthey J.N., Rashid A., Evans D.B. One hundred years after «carcinoid»: epidemiology of and prognostis factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008 Jun 20; 26(18): 3063-72. https://doi.org/10.1200/JCO.2007.15.4377.
3. Gorbunova V.A. Neiroendokrinnye opukholi. Obshchie printsipy diagnostiki i lecheniya. M., 2015, 456.
4. Ramage J.K., Davies A.H., Ardill J., Bax N., Caplin M., Grossman A., Hawkins R., McNicol A.M., Reed N., Sutton R., Thakker R., Aylwin S., Breen D., Britton K., Buchanan K., Corrie P., Gillams A., Lewington V., McCance D., Meeran K., Watkinson A.; UKNETwork for Neuroendocrine Tumours. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005 Jun; 54 Suppl 4: iv1-16. https://doi.org/10.1136/gut.2004.053314.
5. Halfdanarson T.R., Rabe K.G., Rubin J., Petersen G.M. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008 Oct; 19(10): 1727-33. https://doi.org/10.1093/annonc/mdn351.
6. Kim M.K. Neuroendocrine Tumors: A Multidisciplinary Approach. Gastroenterology. 2017; 152(4): 910. https://doi.org/10.1053/j.gastro.2017.01.023.
7. Klimstra D., Arnold R., Capella C. Neuroendocrine neoplasms of the pancreas. WHO Classification of Tumors of the Digestive System. 4th Ed. Lyon: IARC. 2010; 12: 322.
8. Oberg K. Neuroendocrine gastrointestinal tumors A condensed overview of diagnosis and treatment. Ann Oncol. 1999; 10(2): S3-S8. https://doi.org/10.1093/annonc/10.suppl_2.s3.
9. Simonenko V.B., Dudin P.A., Makanin M.A. Neiroendokrinnye opukholi. M., 2010, 237.
10. Shkarban V., Nichitaylo M., Scums A. Surgical treatment of malignant nonfunctioning neuroendocrine tumors of the pancreas. Ann Oncol. 2013 June; 24(4): 85. https://doi.org/10.1093/annonc/mdt203.170.
11. Öberg K.U., Knigge D., Kwekkeboom A., Perrenon behalf of the ESMO Guidelines Working Group. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2012; 23(7): 24-30. https://doi.org/10.1093/annonc/mds295.
12. Halfdanarson T.R., Rabe K.G., Rubin J., Petersen G.M. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival. Ann Oncol. 2008; 19(10): 1727-33. https://doi.org/10.1093/annonc/mdn351.
13. Moertel C.G., Kvols L.K., O’Connell M.J., Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin: evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991; 68: 227-232. https://doi.org/10.1002/1097-0142(19910715)68:2<227::aid-cncr2820680202>3.0.co;2-i.
14. Vilar E., Salazar R., Pérez-García J., Cortes J., Oberg K., Tabernero J. Chemotherapy and role of the proliferation marker ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer. 2007; 14: 221-232. https://doi.org/10.1677/ERC-06-0074.
15. Childs A., Kirkwood A., Edeline J., Luong T.V., Watkins J., Lamarca A., Alrifai D., Nsiah-Sarbeng P., Gillmore R., Mayer A., Thirlwell C., Sarker D., Valle J.W., Meyer T. Ki-67 index and response to chemotherapy in patients with neuroendocrine tumours. Endocr Relat Cancer. 2016; 563-570. https://doi.org/10.1530/ERC-16-0099.
16. Rinke A., Müller H.H., Schade-Brittinger C., Klose K.J., Barth P., Wied M., Mayer C., Aminossadati B., Pape U.F., Bläker M., Harder J., Arnold C., Gress T., Arnold R.; PROMID Study Group. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009 Oct 1; 27(28): 4656-63. https://doi.org/10.1200/JCO.2009.22.8510.
17. Caplin M.E., Pavel M., Ruszniewski P. Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors. N Engl J Med. 2014 Oct 16; 371(16): 1556-7. https://doi.org/10.1056/NEJMc1409757.
18. Yao J.C., Shah M.H., Ito T. A randomized, double-blind, placebocontrolled, multicenter phase III trial of everolimus in patients with advanced pancreatic neuroendocrine tumors (PNET) (RADIANT-3). 35th ESMO Congress; 2010 Oct 8-12; Milan. LBA9.
19. Simonenko V.B., Dulin P.A., Makanin M.A. Vozmozhnosti targetnoi terapii neiroendokrinnykh opukholei. Klinicheskaya meditsina. 2014; 92(8): 5-14.
20. Wimmel A., Wiedenmann B., Rosewicz S. Autocrine growth inhibition by transforming growth factor beta-1 (TGFbeta-1) in human neuroendocrine tumour cells. Gut. 2003 Sep; 52(9): 1308-16. https://doi.org/10.1136/gut.52.9.1308.
21. von Marschall Z., Scholz A., Cramer T., Schafer G., Schirner M., Oberg K., Wiedenmann B., Hocker M., Rosewicz S. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003 Mar 19; 95(6): 437-48. https://doi.org/10.1093/jnci/95.6.437.
22. Chaudhry A., Papanicolaou V., Oberg K., Heldin C.H., Funa K. Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system. Cancer Res.1992; 52: 1006-1012.
23. Wulbrand U., Remmert G., Zofel P., Wied M., Arnold R., Fehmann H.C. mRNA expression patterns of insulin-like growth factor system components in human neuroendocrine tumours. Eur J Clin Invest. 2000; 30: 729-739.
24. von Wichert G., Jehle P.M., Hoeflich A., Koschnick S., Dralle H., Wolf E., Wiedenmann B., Boehm B.O., Adler G., Seufferlein T. Insulinlike growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res. 2000; 60: 4573-4581.
25. Nilsson O., Wangberg B., Theodorsson E., Skottner A., Ahlman H. Presence of IGF-I in human midgut carcinoid tumours--an autocrine regulator of carcinoid tumour growth? Int J Cancer. 1992; 51: 195203. https://doi.org/10.1002/ijc.2910510206.
26. Zhang H., Yee D. The therapeutic potential of agents targeting the type I insulin-like growth factor receptor. Expert Opin Investig Drugs. 2004 Dec; 13(12): 1569-77. https://doi.org/10.1517/13543784.13.12.1569.
27. Kulke M.H., Lenz H.J., Meropol N.J., Posey J., Ryan D.P., Picus J., Bergsland E., Stuart K., Tye L., Huang X., Li J.Z., Baum C.M., Fuchs C.S. Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors. J Clin Oncol. 2008 Jul 10; 26(20): 3403-10. https://doi.org/10.1200/JCO.2007.15.9020.
28. Raymond E., Dahan L., Raoul J.L., Bang Y.J., Borbath I., LombardBohas C., Valle J., Metrakos P., Smith D., Vinik A., Chen J.S., Hörsch D., Hammel P., Wiedenmann B., Van Cutsem E., Patyna S., Lu D.R., Blanckmeister C., Chao R., Ruszniewski P. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011 Feb 10; 364(6): 501-13. https://doi.org/10.1056/NEJMoa1003825.
29. Lloyd R.V., Osamura R.Y., Kloppel G., Rosai J. WHO classification of tumours of endocrine organs. 4th edn. Lyon. IARC Press. 2017.
30. Delektorskaya V.V. Neiroendokrinnye novoobrazovaniya podzheludochnoi zhelezy: novye aspekty morfologicheskoi klassifikatsii (Vsemirnaya organizatsiya zdravookhraneniya, 2017). Uspekhi molekulyarnoi onkologii. 2017; 4(3): 104-108.
31. Modlin I.M., Gustafsson B.I., Moss S.F., Pavel M., Tsolakis A.V., Kidd M. Chromogranin A - biological function and clinical utility in neuroendocrine tumor disease. Ann Surg Oncol. 2010 Sep; 17(9): 2427-43. https://doi.org/10.1245/s10434-010-1006-3.
32. Moiseenko V.M. Zlokachestvennye opukholi: prakticheskie rekomendatsii po lekarstvennomu lecheniyu zlokachestvennykh opukholei (RUSSCO). M., 2017, 656.